Pre-Market Stock Movements Overview

Here’s a look at some notable pre-market stock changes:

Apple — Shares increased by 3.5%. In its fiscal second quarter, Apple reported earnings of $2.01 per share with $111.18 billion in revenue, surpassing analysts’ expectations of $1.95 per share and $109.66 billion in revenue. However, iPhone sales fell below projections for the second time in three quarters.

Roku — The streaming company’s stock surged by 7% after reporting first-quarter revenue of $1.25 billion, exceeding expectations of $1.2 billion. Its adjusted EBITDA was $148.4 million, also above the anticipated $131.3 million, with positive forecasts for the upcoming quarter.

Estée Lauder — Shares jumped over 11% following a better-than-expected third-quarter sales report. Earnings were $0.91 per share and revenue reached $3.71 billion, outpacing forecasts of $0.65 per share and $3.69 billion. The company also noted further job cuts in its turnaround strategy.

Amgen — The biotech firm’s stock fell nearly 2% after only slightly upgrading its full-year outlook. Adjusted earnings are expected to range from $21.70 to $23.10 per share, compared to earlier guidance of $21.60 to $23, but still short of the consensus estimate of $22.33.

Rivian — Shares declined almost 5% despite a first-quarter loss that was bigger than anticipated. The report showed a loss of 33 cents per share on $1.38 billion in revenue, while analysts had expected a loss of 63 cents per share.

Reddit — The social media company’s stock rose by nearly 15%. Daily active users slightly exceeded expectations at 126.8 million, compared to the forecast of 125.9 million. Adjusted EBITDA is anticipated between $285 million and $295 million, surpassing the $275.7 million consensus.

Moderna — Shares climbed 6% following a first-quarter loss of $3.40 per share, which was a better outcome than the expected $4.45 loss. Sales reached $389 million, greatly exceeding the forecast of $236.4 million, and the company reaffirmed its growth target for the year.

Roblox — The online gaming platform’s stock tumbled over 24% after lowering its full-year booking outlook to between $7.33 billion and $7.6 billion, from a previous forecast of $8.28 billion.

Paramount Skydance — Shares increased by 4% after Morgan Stanley upgraded the stock. The bank cited factors like the acquisition of Warner Bros. Discovery and advancements in streaming and studio assets as positive indicators.

SanDisk — The memory company’s shares dropped 5% despite better-than-expected fiscal third-quarter results. Adjusted earnings were $14.54 per share, but this was still below forecasts of $23.41 per share.

Twilio — Shares rose 19% after reporting first-quarter adjusted earnings of $1.50 per share, surpassing the expected $1.27. Revenue of $1.41 billion also exceeded forecasts, and the company anticipates beating estimates in the next quarter.

Clorox — The consumer product company’s stock fell 5.5% despite reporting fiscal third-quarter earnings of $1.64 per share, beating the expected $1.55. Concerns arose regarding potential cuts to its profit outlook due to rising consumer price sensitivity.

Monolithic Power Systems — Shares dipped 2% even after reporting first-quarter earnings of $5.10 per share, which was above expectations.

Western Digital — The data storage company’s stock fell 8% despite reporting better-than-expected quarterly results. It anticipates adjusted earnings in the range of $3.25 per share for the next quarter.

Dexcom — Shares of the continuous blood glucose monitoring maker fell 3% despite beating revenue estimates, reporting $1.19 billion in earnings.

GoDaddy — The website builder’s stock rose 3.5% after posting first-quarter earnings of $1.60 per share, exceeding expectations of $1.52.

Veeva Systems — Shares jumped nearly 10% after the announcement it would join the S&P 500 starting May 7.

Eastman Chemical Company — Shares rose 1.5% after reporting earnings of $1.09 per share, slightly exceeding anticipated earnings.

AstraZeneca — The UK drug company’s shares fell more than 1% after an FDA advisory committee voted against its new cancer drug.